SABCS Spin-Off | 06 - Tripathy

Outside a protocol setting, the combination of lapatinib and capecitabine provides the best potential risk/benefit profile for women with ER-negative, PR-negative, HER2-positive, node-positive disease with cancer recurrence after AC->TH.